Additional Proxy Soliciting Materials (definitive) (defa14a)
November 09 2021 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November
3, 2021
AIKIDO PHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-05576
|
|
52-0849320
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
One
Rockefeller Plaza, 11th Floor,
New York,
NY
|
|
10020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area
code: (212) 745-1374
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☒
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common stock, par value $0.0001 per share
|
|
AIKI
|
|
The NASDAQ Capital Market
|
Item 5.07. Submission of Matters to a Vote of Security Holders.
On November 3, 2021, the board of directors (the “Board”)
of AIkido Pharma Inc., a Delaware corporation (the “Company”) approved an amendment
to the Amended and Restated Bylaws of the Company (the "Amendment"). The Amendment, which was adopted and effective as of November
3, 2021, allows the holders of 33 1/3 of the outstanding shares of stock entitled to vote to constitute a quorum at a meeting of
stockholders for the transaction of any business. Also effective November 3, 2021, the by-laws will now be referred to as the
Amended and Restated Bylaws of AIkido Pharma Inc. to reflect the Company’s name change to AIkido Pharma, Inc. in March 2020. No
other changes were made to our by-laws.
The foregoing description of the Amendment does not purport to be
complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed with this Current
Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.
Item 8.01. Other Events.
The information set forth in Item 5.07 is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
AIKIDO PHARMA, INC.
|
|
|
|
Date: November 9, 2021
|
By:
|
/s/ Anthony Hayes
|
|
Name:
|
Anthony Hayes
|
|
|
Chief Executive Officer
|
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2024 to May 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From May 2023 to May 2024